VLA 1601

Drug Profile

VLA 1601

Alternative Names: VLA-1601; Zika virus vaccine - Emergent BioSolutions/Valneva; ZIKV-VLA1601

Latest Information Update: 22 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Valneva
  • Developer Emergent BioSolutions; Valneva
  • Class Viral vaccines; Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Zika virus infection

Most Recent Events

  • 10 May 2018 Valneva completes enrolment in its phase I trial for Zika virus infection (Prevention, In volunteers) in USA (IM) (NCT03425149)
  • 24 Feb 2018 Phase-I clinical trials in Zika virus infection (Prevention, In volunteers) in USA (IM) (NCT03425149)
  • 07 Apr 2016 Zika virus vaccine - Emergent BioSolutions/Valneva is available for licensing as of 21 Mar 2016. http://www.valneva.com/en/technologies/91
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top